You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

264 Results
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Dec 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Dec 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Dec 2024
Drug
Other Name(s): Gleevec®
Dec 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Dec 2024
Drug
Other Name(s): Camptosar®
Apr 2023
Drug
Other Name(s): Sarclisa®
Mar 2024
Drug
Other Name(s): Abraxane®
Dec 2024
Drug
Other Name(s): Opdualag™
Feb 2025
Drug
Other Name(s): Zejula
Mar 2025

Pages